|
|
|
| Expression and Functional Verification of Nano-antibody Against Porcine Pseudorabies virus gE Protein |
| GUO Yu-Kun1,2, MA Ying-Xian1,2, MING Sheng-Li1,2, GUO Rui-Zhen1,2, YANG Guo-Yu1,2, GUO Yu-Jie1,2,* |
1 College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450002, China;
2 Key Laboratory of Animal Biochemistry and Nutrition, Ministry of Agriculture and Rural Affairs, Henan Agricultural University, Zhengzhou 450002, China |
|
|
|
|
Abstract The outbreak of pseudorabies poses a huge challenge to its prevention and control. The establishment of a new diagnostic method with high specificity and sensitivity and the acquisition of antibodies with virus neutralizing effects are essential for the prevention, control and treatment of the disease. The purpose of this study was to express a soluble nano-antibody against the envelope glycoprotein E (gE) protein of porcine (Sus scrofa) Pseudorabies virus (PRV) in prokaryotic cells and to explore the application of this antibody in the diagnosis and treatment of porcine pseudorabies. In this study, the gene sequence of anti-porcine pseudorabies gE protein antibody was designed and synthesized, which was named PRVgENb, and PRVgENb-pET21b vector was constructed. The fusion protein was expressed in Escherichia coli. After purification on a Ni2+ affinity chromatography column, the single nano-antibody PRVgENb was obtained, which was labeled with HRP for direct ELISA and PRV virus neutralization test. The results showed that the fusion protein PRVgENb had high purity after prokaryotic expression and purification. Direct ELISA results showed that under a certain concentration of antigen, a low concentration of nano-antibody PRVgENb bound to the specific antigen with high activity. While a certain concentration of antibody could sensitively recognize low to high concentrations of specific antigen. The results of the virus neutralization test showed that the nano-antibody PRVgENb inhibited the replication of PRV and had a certain neutralization activity. This experiment established a method to stably obtain the nanobody PRVgENb, and initially explored its use in direct ELISA, and proved that it can inhibit the replication of PRV. Nanobody PRVgENb lays an experimental foundation for the diagnosis, treatment and follow-up research of PRV.
|
|
Received: 31 December 2020
|
|
|
|
Corresponding Authors:
* cngyuj@163.com
|
|
|
|
[1] Arezumand R, Alibakhshi A, Ranjbari J, et al.2017. Nanobodies as novel agents for targeting angiogenesis in solid cancers[J]. Frontiers in Immunology, 8: 1746.
[2] Baral T N, Arbabi-Ghahroudi M.2012. Expression of single-domain antibodies in bacterial systems[J].Methods in Molecular Biology, 911: 257-275.
[3] Behdani M, Zeinali S, Khanahmad H, et al.2012. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor[J].Molecular Immunology, 50(1-2): 35-41.
[4] Djender S, Schneider A, Beugnet A, et al.2014. Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies[J]. Microbial Cell Factories, 13: 140.
[5] He T, Wang Y, Li P, et al.2014. Nanobody-based enzyme immunoassay for aflatoxin in agro-products with high tolerance to cosolvent methanol[J]. Analytical Chemistry, 86(17): 8873-8880.
[6] Hu D, Lv L, Zhang Z, et al.2016. Seroprevalence and associated risk factors of pseudorabies in Shandong province of China[J]. Journal of Veterinary Science, 17(3): 361-368.
[7] Hu D, Zhang Z, Lv L, et al.2015a. Outbreak of variant Pseudorabies virus in Bartha-K61-vaccinated piglets in central Shandong Province,China[J]. Journal of Veterinary Diagnostic Investigation, 27(5): 600-605.
[8] Hu R M, Zhou Q, Song W B, et al.2015b. Novel Pseudorabies virus variant with defects in TK, gE and gI protects growing pigs against lethal challenge[J]. Vaccine, 33(43): 5733-5740.
[9] Jacobs L, Meloen R H, Gielkens A L, et al.1990. Epitope analysis of glycoprotein I of Pseudorabies virus[J]. The Journal of General Virology, 71(Pt 4): 881-887.
[10] Kijanka M, Dorresteijn B, Oliveira S, et al.2015. Nanobody-based cancer therapy of solid tumors[J].Nanomedicine(London, England), 10(1): 161-174.
[11] Kong Q, Yao Y, Chen R, et al.2014. Progress in nanobody and its application in diagnosis[J]. Chinese Journal of Biotechnology, 30(9): 1351-1361.
[12] Li C, Tang Z, Hu Z, et al.2018. Natural single-domain antibody-nanobody: A novel concept in the antibody field[J]. Journal of Biomedical Nanotechnology, 14(1): 1-19.
[13] Liu Q, Wang X, Xie C, et al.2020. A novel human acute encephalitis caused by Pseudorabies virus variant strain[J]. Clinical Infectious Diseases. DOI: 10.1093/cid/ciaa987.
[14] Liu W, Song H, Chen Q, et al.2018a. Recent advances in the selection and identification of antigen-specific nanobodies[J]. Molecular Immunology, 96: 37-47.
[15] Liu Y, Zhang S, Xu Q, et al.2018b. Investigation on pseudorabies prevalence in Chinese swine breeding farms in 2013-2016[J]. Tropical Animal Health and Production, 50(6): 1279-1285.
[16] Maussang D, Mujić-Delić A, Descamps F J, et al.2013. Llama-derived single variable domains (nanobodies) directed against chemokine receptor CXCR7 reduce head and neck cancer cell growth in vivo[J]. The Journal of Biological Chemistry, 288(41): 29562-29572.
[17] Mitchell L S, Colwell L J.2018. Comparative analysis of nanobody sequence and structure data[J].Proteins, 86(7): 697-706.
[18] Steeland S, Vandenbroucke R E, Libert C.2016. Nanobodies as therapeutics: Big opportunities for small antibodies[J]. Drug Discovery Today, 21(7): 1076-1113.
[19] Strauss M, Schotte L, Thys B, et al.2016. Five of five VHHs neutralizing poliovirus bind the receptor-binding site[J]. Journal of Virology, 90(7): 3496-3505.
[20] Sun Y, Liang W, Liu Q, et al.2018. Epidemiological and genetic characteristics of swine Pseudorabies virus in mainland China between 2012 and 2017[J]. PeerJ, 6: e5785.
[21] Tokuhara D, lvarez B, Mejima M, et al.2013. Rice-based oral antibody fragment prophylaxis and therapy against rotavirus infection[J]. The Journal of Clinical Investigation, 123(9): 3829-3838.
[22] Van Heeke G, Allosery K, De Brabandere V, et al.2017. Nanobodies® as inhaled biotherapeutics for lung diseases[J]. Pharmacology & Therapeutics, 169: 47-56.
[23] Van Rooij E M, Haagmans B L, Glansbeek H L, et al.2000. A DNA vaccine coding for glycoprotein B of Pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection[J]. Veterinary Immunology and Immunopathology, 74(1-2): 121-136.
[24] Verpoest S, Cay B, Favoreel H, et al.2017. Age-dependent differences in Pseudorabies virus neuropathogenesis and associated cytokine expression[J]. Journal of Virology, 91(2):e02058.
[25] Vincke C, Gutiérrez C, Wernery U, et al.2012. Generation of single domain antibody fragments derived from camelids and generation of manifold constructs[J]. Methods in Molecular Biology, 907: 145-176.
[26] Wang G S, Du Y, Wu J Q, et al.2018. Vaccine resistant Pseudorabies virus causes mink infection in China[J]. BMC Veterinary Research, 14(1): 20.
[27] Wang H, Li G, Zhang Y, et al.2015. Nanobody-based electrochemical immunoassay for ultrasensitive determination of Apolipoprotein-A1 using silver nanoparticles loaded nanohydroxyapatite as label[J]. Analytical Chemistry, 87(22): 11209-11214.
[28] Wong G, Lu J, Zhang W, et al.2019. Pseudorabies virus: A neglected zoonotic pathogen in humans?[J].Emerging Microbes & Infections, 8(1): 150-154.
[29] Wu C Y, Wu C W, Liao C M, et al.2017. Enhancing expression of the Pseudorabies virus glycoprotein E in yeast and its application in an indirect sandwich ELISA[J]. Journal of Applied Microbiology, 123(3): 594-601.
[30] Wu Q, Zhang H.2018. Seroprevalence and risk factors associated with Pseudorabies virus infection in Tibetan pigs in Tibet[J]. BMC Veterinary Research. 14(1): 25.
[31] Xue X, Fan X, Qu Q, et al.2016. Bioscreening and expression of a camel anti-CTGF VHH nanobody and its renaturation by a novel dialysis-dilution method[J]. AMB Express, 6(1): 72.
[32] Yu Z Q, Tong W, Zheng H, et al.2017. Variations in glycoprotein B contribute to immunogenic difference between PRV variant JS-2012 and Bartha-K61[J]. Veterinary Microbiology, 208: 97-105.
[33] Zarschler K, Witecy S, Kapplusch F, et al.2013. High-yield production of functional soluble single-domain antibodies in the cytoplasm of Escherichia coli[J]. Microbial Cell Factories, 12: 97. |
|
|
|
